title: Neuropsychiatric effects of Parkinson's disease treatment.
abstract: Advances in the treatment of Parkinson's disease have led to significant improvement in many of the disabling motor symptoms of the disease, but often at the cost of neuropsychiatric side-effects. These include psychosis, dopamine dysregulation syndrome, impulse control disorders, mood disorders and Parkinson's disease drug withdrawal syndromes. Such side-effects can be as disabling and have as much impact on activities of daily living, quality of life, relationships and caregiver burden as motor symptoms. Awareness of these potential side-effects is important both in terms of obtaining informed consent, and to aid early identification and intervention, as patients may not spontaneously report side-effects because of lack of insight, or deny them out of shame or embarrassment. The challenge of treatment can be a trade off between the emergence of such side-effects and the amelioration of parkinsonism, best mastered with an informed dialogue between clinician and patient.
authors.affiliation: School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia.
authors.forename: Sallyanne
authors.initials: S
authors.lastname: Aarons
authors.forename: Carmelle
authors.initials: C
authors.lastname: Peisah
authors.forename: Chanaka
authors.initials: C
authors.lastname: Wijeratne
mesh_terms: D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D007174:Disruptive, Impulse Control, and Conduct Disorders / Q000139:chemically induced; D004298:Dopamine / Q000378:metabolism*; D018491:Dopamine Agonists / Q000009:adverse effects; D006801:Humans; D019964:Mood Disorders / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy*; D011605:Psychoses, Substance-Induced; D013375:Substance Withdrawal Syndrome
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D004298:Dopamine